Abstract: Disclosed herein are new crystalline forms of valbenazine ditosylate designated Form D and Form E, which are characterized using one or more analytical methods, such as X-ray Powder Diffraction analysis. Further disclosed herein are crystalline Form D valbenazine ditosylate in the form of a dichloromethane solvate, and crystalline Form E valbenazine ditosylate in the form of a hydrate. Also disclosed are pharmaceutical compositions comprising these new crystalline forms, and methods of using those compositions for the treatment of various disease states and conditions, including hyperkinetic disorder, such as drug-induced tardive dyskinesia and Tourette's syndrome.
Abstract: Chemically and sterically pure synthetic amphiphilic glycoconjugates for neurological use of the formula (I): ##STR1## in which: the saccharide ring represents a monosaccharide such as glucose, galactose or mannose;X represents O or NH and, when X represents O, R is a choline radical whereas, when X represents NH, R is an amino acid or peptide radical; R' represents a saturated or unsaturated linear or branched C.sub.8 -C.sub.18 aliphatic chain, or a ##STR2## group where m is between 7 and 17 and; n is a whole number from 1 to 5.